Highnoon Laboratories Limited (PSX:HINOON)

Market Cap	54.93B +13.4%
Revenue (ttm)	27.71B +12.4%
Net Income	4.13B +21.8%
EPS	77.92 +21.8%
Shares Out	52.98M
PE Ratio	13.31
Forward PE	12.56
Dividend	50.00 (4.82%)
Ex-Dividend Date	Apr 22, 2026

Volume	46,829
Average Volume	54,131
Open	1,029.90
Previous Close	1,028.86
Day's Range	1,021.00 - 1,049.00
52-Week Range	755.56 - 1,241.00
Beta	0.08
RSI	69.60
Earnings Date	Apr 6, 2026

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, allergy, respiratory, and urology; and generic products under various brands. The company operates in Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, Dubai, Sudan, an...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,563
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2025, Highnoon Laboratories's revenue was 27.71 billion, an increase of 12.44% compared to the previous year's 24.64 billion. Earnings were 4.13 billion, an increase of 21.83%.